During the last session, Neogenomics Inc (NASDAQ:NEO)’s traded shares were 0.43 million, with the beta value of the company hitting 1.22. At the end of the trading day, the stock’s price was $14.86, reflecting an intraday gain of 1.36% or $0.2. The 52-week high for the NEO share is $19.11, that puts it down -28.6 from that peak though still a striking 18.44% gain since the share price plummeted to a 52-week low of $12.12. The company’s market capitalization is $1.91B, and the average intraday trading volume over the past 10 days was 1.66 million shares, and the average trade volume was 861.57K shares over the past three months.
Neogenomics Inc (NEO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.67. NEO has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.03.
Neogenomics Inc (NASDAQ:NEO) trade information
Neogenomics Inc (NEO) registered a 1.36% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.36% in intraday trading to $14.86, hitting a weekly high. The stock’s 5-day price performance is 6.29%, and it has moved by -9.45% in 30 days. Based on these gigs, the overall price performance for the year is -6.95%. The short interest in Neogenomics Inc (NASDAQ:NEO) is 3.86 million shares and it means that shorts have 5.35 day(s) to cover.
The consensus price target of analysts on Wall Street is $18.5, which implies an increase of 19.68% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $18 and $19 respectively. As a result, NEO is trading at a discount of -27.86% off the target high and -21.13% off the low.
Neogenomics Inc (NEO) estimates and forecasts
Statistics show that Neogenomics Inc has outperformed its competitors in share price, compared to the industry in which it operates. Neogenomics Inc (NEO) shares have gone down -2.11% during the last six months, with a year-to-date growth rate more than the industry average at 175.00% against 16.50. In the rating firms’ projections, revenue will increase 11.87% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 173.28M as predicted by 9 analyst(s). Meanwhile, a consensus of 10 analyst(s) estimates revenue growth to 173.06M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 155.55M and 156.24M respectively. In this case, analysts expect current quarter sales to grow by 11.40% and then jump by 10.77% in the coming quarter.
While earnings are projected to return 182.09% in 2025.
NEO Dividends
Neogenomics Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Neogenomics Inc (NASDAQ:NEO)’s Major holders
Neogenomics Inc insiders own 1.21% of total outstanding shares while institutional holders control 99.50%, with the float percentage being 100.72%. BLACKROCK INC. is the largest shareholder of the company, while 373.0 institutions own stock in it. As of 2024-06-30, the company held over 19.67 million shares (or 15.5612% of all shares), a total value of $272.82 million in shares.
The next largest institutional holding, with 14.12 million shares, is of VANGUARD GROUP INC’s that is approximately 11.1716% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $195.87 million.
Also, the Mutual Funds coming in first place with the largest holdings of Neogenomics Inc (NEO) shares are iShares Core S&P Smallcap ETF and Vanguard Total Stock Market Index Fund . Data provided on Nov 30, 2024 indicates that iShares Core S&P Smallcap ETF owns about 8.28 shares. This amounts to just over 6.45 percent of the company’s overall shares, with a $123.04 million market value. The same data shows that the other fund manager holds slightly less at 4.0, or about 3.11% of the stock, which is worth about $59.42 million.
